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Abstract
Background: Diabetes mellitus is a growing cause of disease burden globally. Its management is multifaceted, and
adherence to pharmacotherapy is known to play a significant role in glycaemic control. Data on medication
adherence among affected patients is unknown in Cameroon. In this study, the level of adherence and factors influencing
non-adherence to antidiabetic medication among patients with type-2 diabetes was assessed.
Methods: A hospital-based cross-sectional study among adult patients receiving care in the diabetic clinics of the Limbe
and Bamenda Regional Hospitals in Cameroon was conducted. Medication adherence was assessed using the Medication
Compliance Questionnaire (MCQ). Factors associated with non-adherence to medication were determined using basic
and adjusted multivariable logistic regression models.
Results: A total of 195 patients with type 2 diabetes were recruited. The prevalence of non-adherence to medication was
54.4% [95% confidence interval (CI): 47.1–61.5%]. In multivariable analysis, age > 60 years (aO.R. = 0.48, 95% CI: 0.25–0.94),
alcohol consumption (aO.R. = 2.13, 95% CI: 1.10–4.14) and insulin alone therapy (aO.R. = 2.85, 95% CI: 1.01–8.08) were
associated with non-adherence. Patients attributed their non-adherence to forgetfulness (55.6%), lack of finances (38.2%)
and disappearance of symptoms (14.2%).
Conclusions: Adherence to anti-diabetic medication is poor in this study with more than half of participants being non-
adherent. Urgent interventions are required to tackle this problem in combined efforts to stem this looming diabetes
epidemic.
Keywords: Cameroon, Medication adherence, Type 2 diabetes
Background
Diabetes mellitus is undoubtedly one of the fastest gro-
ing public health problems worldwide. According to the
International Diabetes Federation (IDF), there were 415
million people living with diabetes in 2015, with a
projected 642 million by 2040 [1]. Diabetes as was previ-
ously known, is not a disease of the rich, given that
about 77% of the global burden of diabetes is in the low
and middle income countries (LMICs), also significantly
affecting rural and low socioeconomic populations. Also,
diabetes is not only a disease of the elderly as about 50%
of the patients are aged between 40 and 59 years [2]. The
LMICs are faced with the challenge of tackling the growing
burden of diabetes (including other non-communicable dis-
eases) as well as the existing large burden of communicable
and nutritional diseases [3]. By 2015, diabetes was
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responsible for 5 million deaths worldwide, which was far
greater than deaths due to HIV/AIDS, tuberculosis, and
malaria combined [1]. In a recent systematic review, the
prevalence of diabetes in Cameroon stood at 5.8% [4], and
findings from the Global Burden of Disease (GBD) 2016
study revealed that diabetes mellitus accounted for over
132,000 disability adjusted life years (DALY) and about
4000 deaths in Cameroon [5]. These demonstrate that the
burden of diabetes on the society is enormous in terms of
morbidity and mortality, and by extension, a significant im-
pact on the economy and healthcare systems [6].
The management of diabetes is multifaceted including
lifestyle modification, and pharmacotherapy [7]. Nonad-
herence to treatment has been a major huddle in the
management of diabetes by healthcare providers. Also,
the efforts made to explain and improve on adherence
of patients to their treatment are not always effective [8].
Adherence, according to Vrijens et al., is defined as the
extent to which patients are able to follow the recom-
mendations for prescribed treatments [9]. Nonadherence
could occur at different stages of their treatment. These
include not starting the treatment at all, decision not to
fill their prescription in the pharmacy, taking the wrong
dose, or discontinue the treatment earlier than the last
date [8, 9]. Depending on the environment and type of
treatment, the methods of assessing adherence to medi-
cation include electronic monitoring methods, pill
counts, patients and caregiver reports [10].
There have been several studies which have explored
medication adherence to antidiabetic medications with
varying results. A hospital-based study in the United
Arab Emirates reported a prevalence of adherence to an-
tidiabetic medications to be 84% [11]; while similar stud-
ies in Ethiopia and Uganda obtained prevalence of 85.1
and 83.3% respectively [12, 13]. Conversely, studies in
Switzerland and Botswana provided lower prevalence of
40 and 52% respectively [14, 15]. Amongst others, some
factors found to be associated with non-adherence to
antidiabetic medication include financial difficulties, for-
getfulness, younger age, level of education, existing dia-
betes complications and difficulties in taking the
medications alone [11, 14, 16, 17]. The impact and con-
sequences of non-adherence to antidiabetic medications
largely include: increased costs to families especially in
most African countries where healthcare costs are borne
via out of pocket expenditures, increased overall country
healthcare costs, worsening and or increased morbidity,
and death [18–20].
Despite compelling evidence on nonadherence to anti-
diabetic medications and its consequences elsewhere,
there is paucity of information in patients with diabetes
in Cameroon. Therefore, our study aimed to determine
the prevalence and identify factors associated with non-
adherence to antidiabetic medications among patients
with type 2 diabetes mellitus in two regional hospitals of
Cameroon.
Methods
Study design and setting
This was a hospital-based cross-sectional study con-
ducted from August to September 2016 in two regional
hospitals; the Bamenda Regional Hospital (BRH) and the
Limbe Regional Hospital (LRH), in the Northwest and
Southwest regions of Cameroon respectively. Both insti-
tutions are secondary level healthcare facilities and act
as the main referral centres for the respective regions.
The two hospitals have dedicated diabetic clinics which
provide care to persons with diabetes.
Sampling and study participants
A consecutive sampling method was used to recruit eli-
gible participants to the study. Adult (> 18 years) partici-
pants with a confirmed physician diagnosis of type 2
diabetes and receiving treatment during the study period
were included in the study. Participants were recruited
from the out-patient diabetic clinics. Individuals were
excluded if they had acute life-threatening conditions
such as coma or mental impairment which may have
limited their cognitive ability to participate.
Assessment of non-adherence
The Medication Compliance Questionnaire (MCQ)
which has been previously validated for assessing medi-
cation adherence [21] was used. This tool was developed
using a combination of the adherence scales including
the Morisky self-reporting scale [22] and the Hill-Bone
Compliance to High Blood Pressure Therapy Scale [23].
Validity of the MCQ tool has previously been assessed
with a reported Cronbach’s alpha value of 0.782, suggest-
ing acceptable reliability of the tool [21]. This question-
naire has seven questions and assessed patients’
intentional and unintentional nonadherence to medica-
tion instructions including reasons for nonadherence. A
4-point Likert scale for each question was used in the
data collection tools: The response “Never” was given a
score of 4; “sometimes (one to four times per month)”, a
score of 3; “Often (more than five times per month or
more than two times per week)”, a score of 2; “Always”,
a score of 1. A total score for each patient was calculated
which could range from 7 (minimum) to 28 (maximum).
Adherence was defined as a score of 27 or more while
non-adherence was defined by a score less than 27. This
cut-off is guided by scoring system applied in the Mor-
isky Medication Adherence Scale [24], if participants
had taken atleast 95% of prescribed doses. This approach
has been used in previous published studies [21, 24] and
thus helped in comparability of our findings.
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Table 1 Prevalence of non-adherence to antidiabetic medications among patient with type 2 diabetes mellitus in Limbe and
Bamenda Regional Hospitals, Cameroon, 2016
Variable Adherent
n (%)
Non-adherent n (%) Total
N (%)
p-value
Overall, n (%) [95% CI] 89 (45.6)
[38.7–52.5]
106 (54.4)
[47.1–61.5]
Age (in years)
≤ 60 37 (35.9) 66 (64.1) 103(52.8) 0.01
> 60 52 (56.5) 40 (43.5) 92 (47.2)
Educational level (n = 194)
Never 26 (66.7) 13 (33.3) 39 (20.1) 0.03
Primary 35 (42.2) 48 (57.8) 83 (42.8)
Secondary 14 (35.9) 25 (64.1) 39 (20.1)
High school/University 13 (39.4) 20 (60.6) 33 (17.0)
Gender (n = 194)
Male 23 (39.7) 35 (60.3) 58 (29.9) 0.30
Female 65 (47.5) 71 (52.2) 136 (70.1)
Co-morbidity**
Hypertension (n = 121) 58 (47.9) 63 (52.1) 121 (100) 0.35
Chronic renal disease (n = 7) 2 (28.6) 5 (71.4) 7 (100) 0.37*
Heart failure (n = 7) 0 (0.0) 7 (100) 7 (100) 0.01*
Stroke (n = 5) 3 (60) 2 (40) 5 (100) 0.51*
Duration of diabetes (in years) [n = 192]
< 5 years 49 (51.6) 46 (48.4) 95 (49.5) 0.07*
6–10 years 14 (31.8) 30 (68.2) 44 (22.9)
11–20 years 17 (38.6) 27 (61.4) 44 (22.9)
> 20 years 6 (66.7) 3 (33.3) 9 (4.7)
Number of diabetic complications (n = 194)
None 40 (50.0) 40 (50.0) 80 (41.2) 0.54
1 35 (42.7) 47 (57.3) 82 (42.3)
2 or more 13 (40.6) 19 (59.4) 32 (16.5)
Alcohol consumption (n = 194)
Yes 26 (34.7) 49 (65.3) 75 (38.7) 0.02
No 62 (52.1) 57 (47.9) 119 (61.3)
Tobacco use (n = 194)
Yes 1 (33.3) 2 (66.7) 3 (1.5) 0.67*
No 87 (45.5) 104 (54.5) 191 (98.5)
Current antidiabetic medications (n = 192)
Single OHA 43 (53.8) 37 (46.3) 80 (41.7) 0.06
Two OHA 26 (48.2) 28 (51.8) 54 (28.1)
Insulin 7 (26.9) 19 (73.1) 26 (13.5)
Insulin and OHA 11 (34.4) 21 (65.6) 32 (16.7)
Method of glycaemic control (n = 178)
FBS 82 (47.1) 92 (52.9) 174 (97.8) 0.41*
Glycated haemoglobin 0 (0.0) 2 (100) 2 (1.1)
Both 1 (50.0) 1 (50.0) 2 (1.1)
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Other data collected
The adherence tool described above was embedded in a
self-administered data collection form in English lan-
guage. Besides the assessment of medication adherence,
data on socio-demographic characteristics like age, sex
and educational level was obtained. Data on comorbidi-
ties, duration of diabetes, and presence of diabetic com-
plications, treatment or drug type and method of
glycaemic control were also collected. Smoking was de-
fined as any individual who reported smoking at the
time of the study and alcohol consumption was similarly
defined as anyone who reported consuming alcoholic
beverage.
Ethical considerations
This study received approval from the Ethics committee
of the Regional Delegation of the Ministry of Public
Health. The study objectives and aims were in simple
terms explained to eligible participants and only those
who provided their signed consent were included in the
study. All patient confidentiality was maintained and the
study adhered to the World Medical Association’s dec-
laration of Helsinki [25].
Data analysis
Data were entered in Microsoft Excel 2016, and analysed
using Stata IC version 13 statistical package (Texas,
USA). Frequencies and percentages were computed for
categorical variables and group comparisons done using
the chi-squared test (or Fisher’s exact test where appro-
priate). Basic logistic regression models were used to in-
vestigate factors associated with non-adherence to
anti-diabetic medication. Candidate predictor variables
which were significant in the basic models were included
in the multivariable regression model. Statistical signifi-
cance was set at p-value < 0.05.
Results
Sociodemographic characteristics
A total of 195 patients were included in this study. The
mean age was 60.5 ± 13.6 years and 70.3% were women.
One hundred (51.3%) participants were recruited from
the BRH. Seventy-two participants (36.9%) had achieved
at least secondary education.
A total of 98 participants (50.3%) had duration of dia-
betes more than 5 years, and the overall mean body mass
index (BMI) was 28.8 ± 5.4 Kg/m2. The main comorbidi-
ties found were: hypertension (n = 122, 62.6%), chronic
renal disease (n = 7, 3.6%), heart failure (n = 7, 3.6%) and
stroke (n = 5, 2.6%). As concerns the antidiabetic medi-
cations, 80 (41.0%) participants used a single oral
hypoglycaemic drug, and 59 (30.3%) used at least insulin
therapy. One hundred and seventy-four (89.2%) partici-
pants used the fasting blood sugar test as method for
glycaemic control.
Prevalence and reasons for non-adherence to antidiabetic
medication
Overall, 106 participants were non-adherent to antidia-
betic medications with a prevalence of 54.4% (95% confi-
dence interval [CI]: 47.1–61.5%). Forgetfulness (30.2%),
lack of finances (17.4%), disappearance of symptoms
(7.7%) and being too busy (7.7%) were some of the main
reasons highlighted by participants for non-adherence to
their medication. Tables 1 and 2 respectively, present the
prevalence and reasons for non-adherence. Table 3
shows a summary of patient responses to the medication
adherence questions.
Factors associated with non-adherence to antidiabetic
medication
In bivariate analysis, age, educational level, duration of
diabetes, alcohol consumption and insulin therapy were
significantly associated with non-adherence. In multivar-
iable analysis, participants who were aged > 60 years (ad-
justed odds ratio (aO.R.) = 0.48; 95% CI: 0.25–0.94, p =
0.02), participants who consumed alcohol (aO.R. = 2.13;
Table 1 Prevalence of non-adherence to antidiabetic medications among patient with type 2 diabetes mellitus in Limbe and
Bamenda Regional Hospitals, Cameroon, 2016 (Continued)
Variable Adherent
n (%)
Non-adherent n (%) Total
N (%)
p-value
Hospital setting (n = 195)
BRH 46 (46.0) 54 (54.0) 100 (51.3) 0.85
LRH 43 (45.3) 52 (54.7) 95 (48.7)
*Fisher’s exact test, **multiple response, BRH Bamenda Regional Hospital, LRH Limbe Regional Hospital, FBS fasting blood sugar, OHA oral hypoglycaemic agent
Table 2 Reasons for non-adherence to antidiabetic medications
Reasons for non-adherence (n = 133) n (%)
Forgetfulness 59 (44.4)
Lack of finances 34 (25.6)
Drug not effective 2 (1.5)
Side effect of drug 6 (4.4)
Multiple medication 2 (1.5)
Too busy 15 (11.3)
Disappearance of symptoms 15 (11.3)
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1.10–4.14, p = 0.04) and participants on insulin therapy
(aO.R. = 2.85; 1.01–8.08, p = 0.04) were more likely to be
non-adherent to their antidiabetic medication (Table 4).
Discussion
In this cross-sectional study from two regional hospitals
in Cameroon, not up to half of the patients attending
diabetic clinics were adherent to their medication. This
poor adherence to antidiabetic medications was largely
driven by younger age, placement on insulin therapy and
alcohol consumption. Forgetfulness, lack of finances,
disappearance of symptoms and being too busy were the
most frequent reasons given by participants as reasons
for their non-adherence to medication.
More than half (54.4%) of our study participants were
non-adherent to their diabetic medication. While this
might imply a lack of attention people with diabetes give
to their health, it may also reflect limitations in the dia-
betes care model or services in the study hospitals, with
likely pint-sized or no patient counselling on the import-
ance of strict adherence to their medication. Moreover,
the reported prevalence of nonadherence is likely to be
conservative as this was based on patient recall and
self-reports which usually overestimate patient adher-
ence levels. An almost similar result was obtained in
Malaysia, where Ahmad et al. [21] showed that 53% of
their respondents were non-adherent to medication. An-
other study conducted by Abebe et al. in Ethiopia
showed a prevalence of 54.1% [26]. However, much
lower rates of non-adherence have been seen in Uganda
[13], Nigeria [27] and Palestine [28] reporting rates of
16.7, 27.5 and 42% respectively. This difference in adher-
ence levels could be attributed to variations in the health
care services, socio-economic status and metrics used
for assessment of adherence across the study settings.
In multipredictor analysis, patients aged more than 60
years had a 52% significantly lower odds of being
non-adherent to their medication compared to those less
than 60 years. This is in agreement with studies else-
where [29] which showed that non-adherence to medi-
cation is common in younger patients, generally
attributed to challenges with accepting new diagnoses
[30], limited disease knowledge, fear of side effects and
burden of regimens [31]. Older patients with longer dur-
ation of disease are believed to be more aware about the
disease and the importance of glycaemic control to pre-
vent complications and also receive family support for
managing their diabetes [12].
Patients on insulin therapy alone were twice as likely
to be non-adherent compared to participants on oral
hypoglycaemic agents (OHA). The common route of
routine administration of insulin is via subcutaneous in-
jections [32]. As such, fear and pain from the discomfort
of these needle pricks could possibly deter patients from
taking their medication, in part explaining their non-ad-
herence. Also, insulin is much less available compared to
OHAs and access remains poor in many regions of the
world, thereby placing needing patients at risk of
diabetes-related complications and death [13]. Moreover,
affordability remains another challenge as insulin prices
in private pharmacies are fairly high and vary consider-
ably [33]. This would imply that many patients placed
on insulin but who can’t afford are likely to go without
treatment till they are able to purchase their medications
or the next scheduled visit with their health care
provider.
A two-fold increase in non-adherence was associated
with alcohol consumption. Admittedly, alcohol con-
sumption is associated with disadvantageous health be-
haviours, and previous studies have shown that alcohol
use has an inverse relationship with frequency of patient
hospital visits [34]. Our result is somewhat similar to
those of Ahmed and colleagues who found that alcohol
use was associated with poor adherence to diabetes
self-care practices [35].
Among patient reasons for non-adherence to their
medication, close to a third mentioned forgetfulness
while one-sixth of patients indicated it was due to lack
of financial resources for regular medication purchase.
Inability to afford medication has been shown to be a
very common reason for poor adherence [36]. In a na-
tionally representative French study, after adjusting for
Table 3 Patient responses to the Medication Compliance Questionnaire (MCQ)
Questions Responses n (%)
Never Sometimes Often Always
How often do you forget to take your medicine? 98 (50.3) 69 (35.4) 19 (9.7) 9 (4.6)
How often do you decide not to take your medicine? 143 (73.3) 32 (16.4) 13 (6.7) 7 (3.6)
How often do you miss taking your medicine because you feel better? 151 (77.4) 30 (15.4) 6 (3.1) 8 (4.1)
How often do you decide to take less of your medicine? 161 (82.6) 28 (14.4) 4 (2.0) 2 (1.0)
How often do you stop taking your medicine because you feel sick due to side effects of the medicine? 176 (90.3) 12 (6.1) 5 (2.6) 2 (1.0)
How often do you forget to bring along your medicine when you travel away from home? 143 (73.3) 34 (17.5) 12 (6.1) 6 (3.1)
How often do you not take your medicine because you run out of it at home? 120 (61.5) 53 (27.2) 20 (10.3) 2 (1.0)
According to the Likert scale, “Never” = 4, “Sometimes” = 3, “Often” = 2, “Always” = 1
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Table 4 Factors associated with non-adherence to antidiabetic medication among patients with type 2 diabetes in Limbe and
Bamenda Regional Hospitals, Cameroon, 2016
Variable OR (95% CI) Adjusted OR (95% CI) p-value
Age (in years)
≤ 60 0.02*
> 60 0.44 (0.25–0.78) 0.48 (0.25–0.94)
Educational level
Never gone to school
Primary 2.74 (1.24–6.08) 1.71 (0.71–4.10) 0.52*
Secondary 3.57 (1.40–9.08) 1.58 (0.54–4.62)
High school /University 3.08 (1.17–8.07) 1.60 (0.49–5.20)
Gender
Female 0.81*
Male 1.39 (0.75–2.60) 1.07 (0.05–2.28)
Body-Mass Index, BMI (kg/m2) 0.99 (0.97–1.01) 0.55
Co-morbidity
Hypertension 0.35
No
Yes 0.76 (0.42–1.36)
Chronic renal disease
No 0.35
Yes 2.13 (0.40–11.25)
Stroke 0.51
No
Yes 0.54 (0.09–3.34)
Duration of diabetes (in years)
< 5 years 0.22
6–10 years 2.28 (1.08–4.84)
11–20 years 1.69 (0.82–3.50)
> 20 years 0.53 (0.13–2.26)
Alcohol consumption
No 0.04*
Yes 2.05 (1.13–3.72) 2.13 (1.10–4.14)
Tobacco use
No 0.67
Yes 1.67 (0.15–18.76)
Number of diabetic complications
None 0.54
1 1.34 (0.72–2.49)
2 or more 1.46 (0.64–3.35)
Current antidiabetic medications
Single OHA
Two OHA 1.25 (0.63–2.50) 1.16 (0.56–2.42) 0.04*
Insulin alone 3.15 (1.19–8.34) 2.85 (1.01–8.08)
Insulin and OHA 2.22 (0.95–5.20) 0.78 (0.76–4.71)
*p-value on multivariable analysis, OHA oral hypoglycaemic agent, BMI body mass index, ref. reference, OR odds ratio, CI confidence interval
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potential confounders, Tiv and colleagues similarly iden-
tified financial constraint as a determinant for poor
medication adherence among patients with type 2 dia-
betes [16]. Drug costs and affordability are recognized
challenges to controlling chronic disease especially in
low income settings like ours. Jingi et al. previously eval-
uated the costs and affordability of essential medicines
for cardiovascular disease and diabetes care which they
found to be largely unaffordable in the West region of
Cameroon [37].
Forgetfulness has consistently been identified in a
number of studies as a reason for non-adherence to
medication [13, 21]. This may likely be due to the
fact that patients do not receive adequate health edu-
cation or lack appropriate family support. To address
patient forgetfulness, there is need for more regular
follow-up visits, counselling sessions involving a fam-
ily member and even peer group campaigns [38].
Task-shifting via nurse-led approaches and community
health workers for home visits on health education
are likely to significantly improve adherence to medi-
cation, improve glycaemic control and overall health
outcomes. Intervention studies using mobile technol-
ogy for sending motivational message reminders have
demonstrated improved medication adherence among
people with HIV [39]. Policy makers and diabetes
care providers could glean from such successful en-
deavours to improve medication adherence among pa-
tients with diabetes and other chronic diseases.
Overall, Jimmy et al. suggest that identification of in-
dividual patient barriers to medication adherence and
adaptation of suitable techniques may lead to better
drug adherence [40].
This study had some limitations. First, assessment
of medication adherence was based on self-reports
which is liable to recall bias and may overestimate
patient adherence status, when compared to other ob-
jective methods such as pill counts, prescription claim
or biological assays [10]. As such it is highly likely
that our report of non-adherence is a conservative es-
timate. Secondly, using a cross-sectional study design,
our study is limited in establishing temporality and
drawing on causal inferences, but only provides data
on associations. In addition, the use of a convenience
consecutive sampling may have led to selection bias
as not all type 2 diabetes patients in the out-patient
departments will have had follow-up visits during the
recruitment process. As a result, interpretation of our
findings in terms of generalizability should be done
with caution. Furthermore, the small sample size in
this study explained by the low turnout of patients in
the outpatient diabetes clinics of the study centres
highlights the need for larger studies to assess reten-
tion in care of diabetes patients in Cameroon.
Despite these drawbacks, our study has some merits,
as a previously validated [21] medication adherence tool
was used. This is among the few efforts in Africa, and to
the best of our knowledge, the first study in Cameroon
to provide evidence on antidiabetic medication adher-
ence as well as the factors influencing non-adherence
among patients with type 2 diabetes. These findings
will be handy for government and policy makers as
they design strategies for improving diabetes control
in Cameroon.
Conclusions
Our findings show that over half of the patients with
type 2 diabetes receiving care in the two study hospitals
were non-adherent to their anti-diabetic medication.
Non-adherence was associated with being young, alcohol
consumption and insulin only therapy. Key reasons for
non-adherence included forgetfulness and lack of finan-
cial resources to obtain medication. Interventions to im-
prove adherence to anti-diabetic pharmacotherapy and
subsequent attainment of satisfactory glycaemic control,
should include aggressive counselling and health educa-
tion with a focus on younger patients recently diag-
nosed, those on insulin therapy and the control of
unhealthy behaviours. While governments should con-
sider subsidizing costs to make treatment largely afford-
able and available, population interventions targeting
behavioural risk factors should be implemented and or in-
tensified for primary prevention in the wider population.
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